A two-level multimodality imaging Bayesian network approach for classification of partial epilepsy: Preliminary data
Susanne G. Mueller(University of California, San Francisco), Kenneth D. Laxer(California Pacific Medical Center), Miriam Hartig(San Francisco VA Medical Center), Jerome Barakos(Sutter Health), Paul A. Garcia(University of California, San Francisco), Karl Young(University of California, San Francisco)
Cited by 6
Related Papers
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
|Neurology|2009|741
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
|The Lancet Neurology|2010|696
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
|JAMA Neurology|2021|602
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis
|The Lancet Neurology|2012|512
Novel symptomatology and changing epidemiology of domoic acid toxicosis in California sea lions ( <i>Zalophus californianus</i> ): an increasing risk to marine mammal health
|Proceedings of the Royal Society B Biological Sciences|2007|207